“Our findings indicate that the vaccine provided a significant enhanced level of protection against these infections in the target population," the authors concluded. "Furthermore, these results ...
For patients with relapsed or refractory multiple myeloma, treatment with teclistamab plus daratumumab is associated with a significant PFS benefit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback